{"DataElement":{"publicId":"14174541","version":"1","preferredName":"Adverse Event Grading System Grade","preferredDefinition":"The classification system used to indicate the intensity of an unfavorable, unintended consequence associated with a medical treatment, intervention, or procedure.","longName":"14174540v1.00:14174538v1.00","context":"Pediatric Cancer","contextVersion":"1","DataElementConcept":{"publicId":"14174540","version":"1","preferredName":"Adverse Event Grading System","preferredDefinition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).:A morphologic classification system of malignant tumors, usually relating to disease progression and clinical outcome.  It is based upon the presence or absence of several morphologic parameters, including tumor cell necrosis, cytologic atypia, nuclear pleomorphism and mitotic figures, the architectural infiltrating patterns, and the degree of tumor cell differentiation.  Malignant tumors usually are graded I-III.","longName":"2235992v1.00:2431229v1.00","context":"Pediatric Cancer","contextVersion":"1","ObjectClass":{"publicId":"2235992","version":"1","preferredName":"Adverse Event","preferredDefinition":"Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.","longName":"C41331","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-74E9-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-15","modifiedBy":"ONEDATA","dateModified":"2005-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431229","version":"1","preferredName":"Grading System","preferredDefinition":"definition pending","longName":"C48224","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Grading System","conceptCode":"C48224","definition":"A morphologic classification system of malignant tumors, usually relating to disease progression and clinical outcome.  It is based upon the presence or absence of several morphologic parameters, including tumor cell necrosis, cytologic atypia, nuclear pleomorphism and mitotic figures, the architectural infiltrating patterns, and the degree of tumor cell differentiation.  Malignant tumors usually are graded I-III.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCE451-6154-3394-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"01563B78-A2AE-5ACE-E063-731AD00AEF31","latestVersionIndicator":"Yes","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","changeDescription":null,"administrativeNotes":"7/25/23 Created per PCDC metadata template. mr","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"14174538","version":"1","preferredName":"Grading System Grade","preferredDefinition":"A morphologic classification system of malignant tumors, usually relating to disease progression and clinical outcome.  It is based upon the presence or absence of several morphologic parameters, including tumor cell necrosis, cytologic atypia, nuclear pleomorphism and mitotic figures, the architectural infiltrating patterns, and the degree of tumor cell differentiation.  Malignant tumors usually are graded I-III._A position on a scale of intensity or amount or quality.","longName":"14174538v1.00","context":"Pediatric Cancer","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Balis Neuropathy Scale","valueDescription":null,"ValueMeaning":{"publicId":"14174539","version":"1","preferredName":"Balis Pediatric Scale of Peripheral Neuropathies","longName":"14174539v1.00","preferredDefinition":"An instrument used to grade neurotoxicity occurring in children on a 0-4 scale, where the higher number indicates worse neuropathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Balis Pediatric Scale of Peripheral Neuropathies","conceptCode":"C178081","definition":"An instrument used to grade neurotoxicity occurring in children on a 0-4 scale, where the higher number indicates worse neuropathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0156330A-FC5C-5067-E063-731AD00A935D","latestVersionIndicator":"Yes","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0156330A-FC5D-5067-E063-731AD00A935D","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","deletedIndicator":"No"},{"value":"CTCAE","valueDescription":null,"ValueMeaning":{"publicId":"2997910","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","longName":"2997910","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E1B4113-E18D-6785-E040-BB89AD434DDD","latestVersionIndicator":"Yes","beginDate":"2010-01-26","endDate":null,"createdBy":"UMLLOADER_CAAERSPRD","dateCreated":"2010-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0156330A-FC5E-5067-E063-731AD00A935D","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","deletedIndicator":"No"},{"value":"European Society for Blood and Marrow Transplantation (EBMT)","valueDescription":null,"ValueMeaning":{"publicId":"8072459","version":"1","preferredName":"European Society for Blood and Marrow Transplantation","longName":"8072459","preferredDefinition":"A non-profit organization established in 1974 to allow scientists and physicians involved in clinical bone marrow transplantations to share experiences and develop co-operative studies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"European Society for Blood and Marrow Transplantation","conceptCode":"C168842","definition":"A non-profit organization established in 1974 to allow scientists and physicians involved in clinical bone marrow transplantations to share experiences and develop co-operative studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9AC126B-92A1-44DF-E053-4EBD850AC3D0","latestVersionIndicator":"Yes","beginDate":"2022-03-07","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-07","modifiedBy":"ONEDATA","dateModified":"2022-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0156330A-FC5F-5067-E063-731AD00A935D","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","deletedIndicator":"No"},{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"6431768","version":"1","preferredName":"Other","longName":"6431768v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"762A692A-EEF7-29A1-E053-F662850A9EA9","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"WINCHC","dateCreated":"2018-09-18","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0156330A-FC60-5067-E063-731AD00A935D","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","deletedIndicator":"No"},{"value":"Unknown","valueDescription":null,"ValueMeaning":{"publicId":"5682953","version":"1","preferredName":"Unknown","longName":"5682953","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0FC6-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0156330A-FC61-5067-E063-731AD00A935D","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","deletedIndicator":"No"},{"value":"Not Reported","valueDescription":null,"ValueMeaning":{"publicId":"5612322","version":"1","preferredName":"Not Reported","longName":"5612322v1.00","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45340835-3B00-7C78-E053-F662850A44F9","latestVersionIndicator":"Yes","beginDate":"2017-01-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-01-03","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"10/10/23 changed Long Name from \"Not Stated\" to match NCIt Preferred name and current caDSR concept Long Name of \"Not Reported\" per Brenda.Janice . LS","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0156330A-FC62-5067-E063-731AD00A935D","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"14174537","version":"1","preferredName":"Tumor Grading System Grade","preferredDefinition":"A morphologic classification system of malignant tumors, usually relating to disease progression and clinical outcome.  It is based upon the presence or absence of several morphologic parameters, including tumor cell necrosis, cytologic atypia, nuclear pleomorphism and mitotic figures, the architectural infiltrating patterns, and the degree of tumor cell differentiation.  Malignant tumors usually are graded I-III._A position on a scale of intensity or amount or quality.","longName":"14174537v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Grading System","conceptCode":"C48224","definition":"A morphologic classification system of malignant tumors, usually relating to disease progression and clinical outcome.  It is based upon the presence or absence of several morphologic parameters, including tumor cell necrosis, cytologic atypia, nuclear pleomorphism and mitotic figures, the architectural infiltrating patterns, and the degree of tumor cell differentiation.  Malignant tumors usually are graded I-III.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0156257B-FC8F-4EB8-E063-731AD00A907B","latestVersionIndicator":"Yes","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"0156257B-FC90-4EB8-E063-731AD00A907B","latestVersionIndicator":"Yes","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"COLBERTM","dateModified":"2023-07-25","changeDescription":null,"administrativeNotes":"7/25/23 Created per PCDC metadata template. mr","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"12173174","version":"1","longName":"PCDC Aggregated Dictionary","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"12173181","version":"1","longName":"Events","context":"Pediatric Cancer"},{"publicId":"12173218","version":"1","longName":"Adverse Events","context":"Pediatric Cancer"}]},{"publicId":"13954630","version":"1","longName":"All Pediatric Core CDEs","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"14599256","version":"1","longName":"Clinical Observation","context":"Pediatric Cancer"}]}],"AlternateNames":[{"name":"AE_GRADE_SYSTEM","type":"PCDC Alt Name","context":"Pediatric Cancer"},{"name":"Grading System","type":"Ped Cancer Alt Name","context":"Pediatric Cancer"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Grading System","url":null,"context":"Pediatric Cancer"}],"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"0156474F-0227-5C43-E063-731AD00A879C","latestVersionIndicator":"Yes","beginDate":"2023-07-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-07-25","modifiedBy":"FINCHAMB","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2/22/24 Added Ped Core Alts, CSI per PCDC/MW recommendations. BF","unresolvedIssues":null,"deletedIndicator":"No"}}